Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 769-780 , December 2006

Thalidomide and lenalidomide in multiple myeloma

References 

  1. Kyle RA, Rajkumar SV. Multiple myeloma. The New England Journal of Medicine. 2004;351:1860–1873
  2. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. The New England Journal of Medicine. 2003;349:2495–2502
  3. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. The New England Journal of Medicine. 1999;341:1565–1571
  4. Raje N, Anderson K. Thalidomide–a revival story. The New England Journal of Medicine. 1999;341:1606–1609
  5. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96:2943–2950
  6. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210–216
  7. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nature Reviews Cancer. 2002;2:927–937
  8. Bartlett JB, Tozer A, Stirling D, et al. Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. British Journal of Cancer. 2005;93:613–619
  9. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98:492–494
  10. Yakoub-Agha I, Attal M, Dumontet C, et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients–report of the Intergroupe Francophone du Myelome (IFM). The Hematology Journal. 2002;3:185–192
  11. Neben K, Moehler T, Kraemer A, et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. British Journal of Haematology. 2001;115:605–608
  12. Mileshkin L, Biagi JJ, Mitchell P, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood. 2003;102:69–77
  13. Kumar S, Gertz MA, Dispenzieri A, et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clinic Proceedings. 2003;78:34–39
  14. Schey SA, Cavenagh J, Johnson R, et al. An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leukemia Research. 2003;27:909–914
  15. Hus M, Dmoszynska A, Soroka-Wojtaszko M, et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica. 2001;86:404–408
  16. Tosi P, Zamagni E, Cellini C, et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica. 2002;87:408–414
  17. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Annals of Oncology. 2001;12:991–995
  18. Palumbo A, Bertola A, Falco P, et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. The Hematology Journal. 2004;5:318–324
  19. Anagnostopoulos A, Weber D, Rankin K, et al. Thalidomide and dexamethasone for resistant multiple myeloma. British Journal of Haematology. 2003;121:768–771
  20. Coleman M, Leonard J, Lyons L, et al. BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia. Leukemia and Lymphoma. 2002;43:1777–1782
  21. Yakoub-Agha I, Hulin C, Doyen L, et al. A multicenter prospective randomized study testing non-inferiority of thalidomide 100mg/day as compared with 400mg/day in patients with refractory/relapsed multiple myeloma: first results of the final analysis of the IFM 01-02 study. Blood. 2005;106:364a
  22. Offidani M, Corvatta L, Marconi M, et al. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica. 2006;91:133–136
  23. Kropff MH, Lang N, Bisping G, et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. British Journal of Haematology. 2003;122:607–616
  24. Moehler TM, Neben K, Benner A, et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood. 2001;98:3846–3848
  25. Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. Journal of Clinical Oncology. 2003;21:2732–2739
  26. Zangari M, Barlogie B, Burns M, et al. Velcade (V)-thalidomide (T)-dexamethasone (D) for advanced and refractory multiple myeloma (MM): Long-term follow-up of phase I-II Trial UARK 001-37: Superior outcome in patients with normal cytogenetics and no prior T. Blood. 2005;106:2552a
  27. Richardson P, Jagannath S, Hussein M, et al. A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; preliminary results. Blood. 2005;106:1565a
  28. Richardson P, Jagannath S, Schlossman R, et al. A multi-center, randomized, phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for the treatment of relapsed or refractory multiple myeloma (MM). Blood. 2003;102:825a
  29. Dimopoulos M, Spencer A, Attal M, et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010). Blood. 2005;106:6a
  30. Richardson P, Schlossman R, Munshi N, et al. A phase 1 trial of lenalidomide with bortezomib in relapsed and refractory multiple myeloma. Blood. 2005;106:365a
  31. Rajkumar SV, Gertz M, Lacy M, et al. Thalidomide as initial therapy for early stage myeloma. Leukemia. 2003;17:775–779
  32. Weber D, Rankin K, Gavino M. Thalidomide alone or with dexamethasone for previously untreated myeloma. Journal of Clinical Oncology. 2003;21:16–19
  33. Rajkumar SV, Hayman S, Gertz M, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of Clinical Oncology. 2002;20:4319–4323
  34. Cavo M, Zamagni E, Tosi P, et al. First line therapy with thalidomide and dexamethasone in preparation for autologous transplant for multiple myeloma. Haematologica. 2004;89:826–831
  35. Rajkumar SV, hayman S, Lacy M, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106:4050–4053
  36. Niesvizky R, Pekle K, Gelbshtein U, et al. BIRD (Biaxin Revlimid Dex) combination therapy results in high response rate in myeloma. Blood. 2005;642:106a
  37. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical truial of Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed myeloma. Journal of Clinical Oncology. 2006;24:1–6
  38. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide–dexamethasone over vincristine–doxorubicin–dexamethasone (VAD) as primary therapy in preparation for transplantation in myeloma. Blood. 2005;106:35–39
  39. Wang M, Delasalle K, Giralt S, Alexanian R. Rapid control of previously untreated multiple myeloma with bortezomib–thalidomide–dexamethasone followed by early intensive therapy. Blood. 2005;106:784a
  40. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic cell transplantation for multiple myeloma. The New England Journal of Medicine. 2006;354:1021–1030
  41. Barlogie B, Tricot G, Rasmussen E, et al. Total therapy 3 (TT3) incorporating Velcade into upfront management of myeloma. Blood. 2005;106:1154a
  42. Palumbo A, Bringhen S, Musto P, et al. Oral melphalan, prednisone and thalidomide in multiple myeloma. Blood. 2005;106:779a
  43. Facon T, Mary JY, Hulin C, et al. Major superiority of melphalan–prednisone (mp)+ thalidomide (thal) over mp and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood. 2005;106:780a
  44. Palumbo A, Falco P, Musto P, et al. Oral Revlimid plus melphalan–prednisone for newly diagnosed myeloma. Blood. 2005;106:785a
  45. Berenson J, Crowley J, Grogan T, et al. Maintenance therapy with alternate day prednisone improves survival in multiple myeloma patients. Blood. 2002;99:3163–3168
  46. Shustik C, Belch A, Robinson S, et al. Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: A National Cancer Institute Of Canada Clinical Trials Group Study: MY.7. Journal of Clinical Oncology. 2004;22:6510a;(supplement 14)
  47. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance treatment with thalidomide after autologous transplantation for myeloma: final analysis of a prospective randomized study of the ‘Intergroupe Francophone du Myelome’. Blood. 2005;106:1148a
  48. Stewart AK, Chen CI, Howson-Jan K, et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clinical Cancer Research. 2004;10:8170–8176
  49. Fakhouri F, Guerraoui H, Presne C, et al. Thalidomide in patients with myeloma and renal failure. British Journal of Haematology. 2004;125:96–97
  50. Tosi P, Zamagni E, Cellini C, et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. European Journal of Haematology. 2004;73:98–103
  51. Harris E, Behrens J, Samson D, et al. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. British Journal of Haematology. 2003;122:160–161
  52. Matthews SJ, McCoy C. Thalidomide: a review of approved and investigational uses. Clinical Therapeutics. 2003;25:342–395
  53. Apfel SC, Zochodne DW. Thalidomide neuropathy: too much or too long?. Neurology. 2004;62:2158–2159
  54. Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002;100:1168–1171
  55. Zangari M, Anaissie E, Barlogie B. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614–1615
  56. Zonder JA, Durie BGM, McCoy J, et al. High incidence of thrombotic events observed in patients receiving lenalidomide (L) + dexamethasone (D) (LD) as first-line therapy for multiple myeloma (MM) without aspirin (ASA) prophylaxis. Blood. 2005;106:3455a
  57. Richardson PG, Schlossman RL, Weller E. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063–3067
  58. List AF. Emerging data on IMiDS in the treatment of myelodysplastic syndrome. Seminars in Oncology. 2005;32:31–35

PII: S1521-6926(06)00043-0

doi: 10.1016/j.beha.2006.06.006

Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 769-780 , December 2006

Article Tools